DOSIsoft SA, a France-based leading dosimetry manufacturer specialized in patient-specific imaging and dosimetry software solutions for radiation oncology & nuclear medicine, and Oncosia Scientific GmbH, a German-based provider of dosimetry services and solutions across clinical routine, research, and trials for both diagnostic and therapeutic applications in nuclear medicine, announce their partnership to commercialize and distribute PLANET® Onco Dose in German and Turkish markets.
PLANET® Onco Dose, version 3.2, is a molecular imaging and voxel-based dosimetry solution dedicated to Targeted Radionuclide Therapies (TRT), now approved to be marketed in the EU under the CE MDR Mark.
Under the distribution agreement signed on March 27th, 2025, Oncosia Scientific GmbH becomes the official distributor of PLANET® Onco Dose in Germany and Türkiye, and is committed to accelerating market awareness and developing business opportunities. With a team of experienced clinical experts — including key opinion leader roles in these countries and more globally across Europe — Oncosia Scientific GmbH will provide distribution, training, and support services for PLANET® Onco Dose, as well as dosimetry services in the field of medical physics, clinical studies of radiopharmaceutical cancer diagnostics & therapy, and routine clinical applications.
"We are excited to share our vision with Oncosia — elevating personalized treatment planning and dosimetry in nuclear medicine. This partnership creates a close collaboration regarding marketing and sales activities and a joint mission to bring the MDR-compliant and unique features of PLANET® Onco Dose to these very important German and Turkish markets."
Marc Uszynski — CEO, DOSIsoft
"The recent Annual Turkish Congress of Nuclear Medicine in Antalya, in which we participated, confirmed that Türkiye is a rapidly growing market where a high number of Selective Internal Radiation Therapy (SIRT) and Molecular Radiotherapy (MRT) procedures are performed annually. We see the same trend in Germany.
We're pleased to partner with DOSIsoft — a well-known dosimetry market leader — to see the German and Turkish community benefit from the latest innovations of PLANET® Onco Dose: personalized dosimetry for radioembolization & MRT with support for radionuclides such as ⁹⁰Y, ¹⁷⁷Lu, ¹⁶⁶Ho and ¹³¹I. It further prepares Oncosia Scientific to participate as a dosimetry vendor in clinical trials with a CE-marked in-house dosimetry solution."
Nico Schürrle — CEO, Oncosia Scientific GmbH
PLANET® Onco Dose Edition 3 is developed by DOSIsoft SA in France. It is a Class IIb CE-marked medical device under MDR (EU) 2017/745 since February 17th, 2025, and US FDA 510(k) cleared since March 14th, 2025. Availability of the product or specific features may vary by country and regulatory approval status. CE MDR Certificate No. 40168 was issued by GMED, a notified body with identification number CE 0459.
Founded in 2002, DOSIsoft stands as a market leader specialized in dosimetry software for radiation oncology and nuclear medicine, improving cancer patient safety and treatment quality. DOSIsoft provides patient-specific quality assurance and medical imaging solutions in over 600 hospital centers in 60 countries. A spin-off of Gustave Roussy and the Curie Institute in France, DOSIsoft constantly innovates in partnership with leading cancer institutes and research centers worldwide — including recently through the Thera4Care European project. www.dosisoft.com
Oncosia Scientific was founded in 2024 with the mission of integrating personalized medicine into healthcare — with a special focus on the prevention, early detection, diagnosis, and treatment of cancer. Our innovative solutions are designed for both patients and physicians, grounded in scientific evidence to ensure individualized and optimal care.